The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EXEL | +43.49% | +90.88% | +13.8% | +163% |
| S&P | +18.37% | +110.18% | +16.02% | +358% |
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
This innovative drugmaker still has plenty of upside potential.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $568.26M | -10.8% |
| Gross Profit | $548.79M | -11.4% |
| Gross Margin | 96.57% | -0.7% |
| Market Cap | $12.02B | 83.6% |
| Market Cap / Employee | $10.48M | 0.0% |
| Employees | 1.1K | -12.4% |
| Net Income | $184.85M | -18.3% |
| EBITDA | $220.92M | -22.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $121.08M | -23.1% |
| Accounts Receivable | $292.35M | -26.3% |
| Inventory | 23.5 | 13.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $179.84M | -9.2% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 22.10% | 10.3% |
| Return On Invested Capital | 10.54% | 0.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $46.16M | -59.1% |
| Operating Free Cash Flow | $48.99M | -59.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 16.54 | 19.17 | 15.68 | 22.13 | 15.04% |
| Price to Book | 3.26 | 4.18 | 4.63 | 5.69 | 82.60% |
| Price to Sales | 3.64 | 4.60 | 4.33 | 5.89 | 79.44% |
| Price to Tangible Book Value | 3.35 | 4.30 | 4.77 | 5.86 | 82.59% |
| Price to Free Cash Flow TTM | 17.49 | 14.85 | 12.14 | 17.41 | -26.87% |
| Enterprise Value to EBITDA | 33.65 | 53.05 | 46.95 | 56.64 | 176.96% |
| Free Cash Flow Yield | 5.7% | 6.7% | 8.2% | 5.7% | 36.74% |
| Return on Equity | 20.2% | 23.1% | 30.2% | 29.0% | 92.57% |
| Total Debt | $194.45M | $215.83M | $187.13M | $179.84M | -9.18% |
EXEL earnings call for the period ending December 31, 2024.
EXEL earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
